Video

Peter Lio, MD: Managing and Treating Itch

Author(s):

Peter Lio, MD, discusses conventional therapeutic options for pruritus.

The treatments for itch can be just as numerous as the underlying causes.

In the latest episode of Derm Discussions, Peter Lio, MD, Clinical Assistant Professor of Dermatology & Pediatrics, Northwestern University Feinberg School of Medicine, discussed the different ways itch can be treated.

“I think the first thing is that we want to see as best we can to try to understand what is mediating itch,” Lio said. “In those 4 categories, is there an underlying dermatologic disease—particularly inflammatory disease—that we can approach? Is there some kind of a neuropathy? Do we need to focus on nerves? Is it psychogenic? Is it systemic?”

He acknowledged that treatment can be especially difficult if the clinician is faced with pruritis sin materia — or itch without a rash.

In this instance, work-up and screenings are warranted; and even then, patients may still find themselves in a position where the symptom cannot be managed.

Lio described his therapeutic ladder, which begins with topical medications and proceeds with “safe systemics” and more powerful systemics.

He also explained his approach as integrative, sometimes incorporating topical corticosteroids if the underlying cause is mediated by inflammation or the immune system. Depending on cause, other options include calcineurin inhibitors and topical anesthetics.

Options for systemic chronic itch include antihistamines, gabapentin, antidepressants, NK1 inhibitors, opioid modulators, and naltrexone.

Listen to the full podcast episode below:

Related Videos
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Safety Data on Dupilumab, Ensifentrine for COPD, with MeiLan Han, MD
Muthiah Vaduganathan, MD, MPH | Credit: Brigham and Women's Hospital
© 2024 MJH Life Sciences

All rights reserved.